Skip to main content

Table 1 Treatment response and FLT3 mutations of the 6 patients with FLT3-ITD-positive AML

From: Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation

Caseno.

Sex/age

Karyotype

Additional mutations

Sorafenib maintenance

Follow-up post allo-HSCT (M)

Response

FLT3 mutation

Diagnosis

AF

Relapse

AF

#1

M/52

46, XY

None

Yes

13.0

CCR

FLT3-ITD

0.62

NA

 

#2

F/28

46, XY

TET2

Yes

8.0

CCR

FLT3-ITD

0.76

NA

 

#3

M/39

47, XY,  + 10

DNMT3A, NPM1, SOCS1

Yes

13.5

Relapse

FLT3-ITD

0.52

FLT3-ITD

0.39

#4

F/23

46, XX, t(11;20)(p15;q11)

TET2, RUNX1

Yes

10.0

Relapse

FLT3-ITD

0.43

FLT3-ITD + D835

0.30

#5

M/23

47, XY,  + 8

TET2

Yes

11.5

Relapse

FLT3-ITD

0.66

FLT3-ITD

0.41

#6

M/43

46, XY

EZH2, RUNX1, BCL6

Yes

7.0

Relapse

FLT3-ITD

0.75

WT

 
  1. Allo-HSCT allogenetic hematopoietic stem cell transplantation; M months; AF allele frequency; M male; CCR continued complete response; NA not available; F female; WT wild type